D. E. Shaw & Co. Inc. boosted its stake in shares of Akebia Therapeutics Inc (NASDAQ:AKBA) by 297.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 417,178 shares of the biopharmaceutical company’s stock after acquiring an additional 312,207 shares during the quarter. D. E. Shaw & Co. Inc.’s holdings in Akebia Therapeutics were worth $2,307,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Akebia Therapeutics by 57.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,812 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 2,835 shares during the last quarter. Great West Life Assurance Co. Can grew its stake in shares of Akebia Therapeutics by 80.1% during the fourth quarter. Great West Life Assurance Co. Can now owns 8,418 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 3,743 shares during the last quarter. Advisor Group Inc. grew its stake in shares of Akebia Therapeutics by 3,206.3% during the fourth quarter. Advisor Group Inc. now owns 9,919 shares of the biopharmaceutical company’s stock valued at $54,000 after buying an additional 9,619 shares during the last quarter. HL Financial Services LLC bought a new position in shares of Akebia Therapeutics during the fourth quarter valued at approximately $56,000. Finally, Two Sigma Securities LLC bought a new position in shares of Akebia Therapeutics during the fourth quarter valued at approximately $57,000.

Shares of NASDAQ AKBA opened at $7.16 on Thursday. Akebia Therapeutics Inc has a 52-week low of $5.20 and a 52-week high of $11.60.

A number of research analysts have recently commented on AKBA shares. ValuEngine cut Akebia Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 18th. BidaskClub cut Akebia Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, December 25th. Finally, Zacks Investment Research raised Akebia Therapeutics from a “hold” rating to a “buy” rating and set a $6.75 target price on the stock in a research note on Tuesday, January 15th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company’s stock. Akebia Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $14.28.

ILLEGAL ACTIVITY WARNING: This piece of content was first posted by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2019/04/04/d-e-shaw-co-inc-has-2-31-million-holdings-in-akebia-therapeutics-inc-akba.html.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with renal disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease in dialysis and non-dialysis patients.

Further Reading: Outstanding Shares, Buying and Selling Stocks

Want to see what other hedge funds are holding AKBA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Akebia Therapeutics Inc (NASDAQ:AKBA).

Institutional Ownership by Quarter for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.